CN Patent

CN117120449A — 用于癌症治疗的联合疗法

Assigned to Yirui Shikang Pharmaceutical Research And Development Co · Expires 2023-11-24 · 2y expired

What this patent protects

本公开提供了用SHP2抑制剂和KRAS G12C抑制剂的联合疗法来治疗癌症的方法。

USPTO Abstract

本公开提供了用SHP2抑制剂和KRAS G12C抑制剂的联合疗法来治疗癌症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117120449A
Jurisdiction
CN
Classification
—
Expires
2023-11-24
Drug substance claim
No
Drug product claim
No
Assignee
Yirui Shikang Pharmaceutical Research And Development Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.